Fox Run Management’s Niagen Bioscience NAGE Stock Holding History

Fox Run Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31,608	Closed	-$135K	–	1373
2026 Q1	$135K	Buy	+31,608	New	+$171K	0.02%	813

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fox Run Management's NAGE Position: Q2 2026 in Review

Fox Run Management sold out of Niagen Bioscience (NAGE) in Q2 2026, closing a stake of 31,608 shares — an estimated $135K sold.

Fox Run Management first reported a position in NAGE in Q1 2026 and held it in 1 quarter. The position peaked at $135K in Q1 2026. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Fox Run Management reported no remaining Niagen Bioscience position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 31,608 Niagen Bioscience shares in Q2 2026, an estimated $135K.
Fox Run Management first reported a position in Niagen Bioscience in Q1 2026 and held it in 1 quarter.
Fox Run Management's Niagen Bioscience position peaked at $135K in Q1 2026.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.